2007•Zhongguo yaofangRequires access

Interferon vs. Lamivudine for Chronic Type B Hepatitis: Analysis of Cost-Effectiveness

Yan Xu

Abstract

OBJECTIVE: To evaluate the pharmacoeconomic effectiveness of interferon vs.lamivudine for chronic Type B hepatitis.METHODS: The cost-effectiveness analysis was carried out to evaluate two therapeutic schemes for chronic Type B hepatitis,and Bootstrap analysis was performed for sensitivity analysis.RESULTS: The cost-effectiveness ratios of interferon and lamivudine were 9 128.31 and 11 491.70,respectively.As compared with low cost interferon group,the incremental cost-effectiveness ratio in lamivudine group was 45 727.01.The median of incremental cost in lamivudine group obtained from Bootstrap analysis was 46 236.24.CONCLUSION: Pharmacoeconomically,interferon scheme is optimal for chronic Type B hepatitis in spite of its lower effectiveness rate as compared with lamivudine scheme.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Lamivudine, Chronic hepatitis, Medicine, Interferon, Cost-effectiveness analysis, Internal medicine, Gastroenterology, Hepatitis B